Screener
Protagonist Therapeutics PTGX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.00001 par value, 180,000,000 shares authorized; 64,672,032 and 62,577,897 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 1 | 1 |
| Additional paid-in capital | 1,146,409 | 1,084,736 |
| Accumulated other comprehensive (loss) income | (828) | 641 |
| Accumulated deficit | (304,039) | (470,671) |
| Total stockholders’ equity | 841,543 | 614,707 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's common stock?
- Protagonist Therapeutics (PTGX) reported common stock of $1K in Q2 2026.
- How has Protagonist Therapeutics's common stock changed year-over-year?
- Protagonist Therapeutics's common stock decreased by 0.0% year-over-year, from $1K to $1K.
- What is the long-term trend for Protagonist Therapeutics's common stock?
- Over 2 years (2023 to 2025), Protagonist Therapeutics's common stock has grown at a 0.0% compound annual growth rate (CAGR), from $1K to $1K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Protagonist Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude